Skip to content
Vyndamax, Vyndaqel(tafamidis)
Vyndamax, Vyndaqel (tafamidis) is a small molecule pharmaceutical. Tafamidis was first approved as Vyndaqel on 2011-11-16. It has been approved in Europe to treat amyloidosis. It is known to target transthyretin.
Download report
Favorite
FDA Novel Drug Approvals 2019
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nutritional and metabolic diseasesD009750
Trade Name
FDA
EMA
Vyndamax, Vyndaqel
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Tafamidis
Tradename
Company
Number
Date
Products
VYNDAMAXFoldRx PharmaceuticalsN-212161 RX2019-05-03
1 products, RLD, RS
Tafamidis meglumine
Tradename
Company
Number
Date
Products
VYNDAQELFoldRx PharmaceuticalsN-211996 RX2019-05-03
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
vyndamax vyndaqelNew Drug Application2020-04-22
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
TAFAMIDIS, VYNDAMAX, FOLDRX PHARMS
2026-05-03ODE-237
2024-05-03NCE
TAFAMIDIS MEGLUMINE, VYNDAQEL, FOLDRX PHARMS
2026-05-03ODE-237
2024-05-03NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Tafamidis, Vyndamax, Foldrx Pharms
97704412035-08-31DS, DPU-2524
72146952024-04-27DS, DP
72146962023-12-19U-2524
Tafamidis Meglumine, Vyndaqel, Foldrx Pharms
86531192024-01-28U-2524
81686632023-12-19DS, DP
ATC Codes
N: Nervous system drugs
N07: Other nervous system drugs in atc
N07X: Other nervous system drugs in atc
N07XX: Other nervous system drugs in atc
N07XX08: Tafamidis
HCPCS
No data
Clinical
Clinical Trials
33 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Familial amyloid neuropathiesD028227E85.1222
Amyloid neuropathiesD01777211
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CardiomyopathiesD009202EFO_0000318I4211
Nervous system lead poisoning adultD02026511
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients1414
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Takotsubo cardiomyopathyD054549EFO_1002000I51.8111
PolyneuropathiesD011115EFO_0009562A69.2211
Hereditary amyloidosis transthyretin-relatedC56778211
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTAFAMIDIS
INNtafamidis
Description
Tafamidis is a member of the class of 1,3-benzoxazoles that is 1,3-benzoxazole-6-carboxylic acid in which the hydrogen at position 2 is replaced by a 3,5-dichlorophenyl group. Used (as its meglumine salt) for the amelioration of transthyretin-related hereditary amyloidosis. It has a role as a central nervous system drug. It is a member of 1,3-benzoxazoles, a monocarboxylic acid and a dichlorobenzene. It is a conjugate acid of a tafamidis(1-).
Classification
Small molecule
Drug classantimyloidotics
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
O=C(O)c1ccc2nc(-c3cc(Cl)cc(Cl)c3)oc2c1
Identifiers
PDB6E72
CAS-ID594839-88-0
RxCUI1545063
ChEMBL IDCHEMBL2103837
ChEBI ID78538
PubChem CID11001318
DrugBankDB11644
UNII ID8FG9H9D31J (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
TTR
TTR
Organism
Homo sapiens
Gene name
TTR
Gene synonyms
PALB
NCBI Gene ID
Protein name
transthyretin
Protein synonyms
ATTR, epididymis luminal protein 111, Prealbumin, prealbumin, amyloidosis type I, TBPA, thyroxine-binding prealbumin
Uniprot ID
Mouse ortholog
Ttr (22139)
transthyretin (P07309)
Variants
Clinical Variant
No data
Financial
Vyndaqel - Pfizer
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,397 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
29,624 adverse events reported
View more details